VivoSeq
Oncology

Neuroendocrine Carcinoma

82

Pipeline Programs↗

29

Active Trials↗

37

Companies Involved↗

Neuroendocrine Carcinoma is a moderately active landscape with 82 programs across 37 companies. The most active players are Shanghai Simnova Biotechnology Co.,Ltd., Shanghai Henlius Biotech, Eli Lilly. 5 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

30/100

Mech. Concentration

17/100

Completion Rate

72/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shanghai Simnova Biotechnology Co.,Ltd.

1 program

Phase 1Shanghai Henlius Biotech logo

Shanghai Henlius Biotech

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1N

Novatek Pharmaceuticals

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

5 programs

Phase 2Pfizer logo

Pfizer

4 programs

Phase 2

Pipeline

Programs by Phase

Preclinical2

Retifanlimab

Incyte

Sintilimab，surufatinib

Tianjin Medical University Cancer Institute and Hospital

Phase 18

Serplulimab

Shanghai Henlius Biotech

Tocilizumab

Roche

Cixutumumab

Eli Lilly

Octreotide Acetate

Novartis

Seneca Valley Virus-001

Children's Oncology Group

Phase 258

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Avelumab

EMD Serono

Paclitaxel

Teva

Cabozantinib

Bristol-Myers Squibb

Phase 39

Selinexor

Karyopharm Therapeutics Inc

Toripalimab

Coherus Oncology, Inc.

Tarlatamab

Amgen

Surufatinib

Hutchison Medipharma Limited

Axitinib

Prism Pharmaceuticals

Approved5

Carfilzomib

Virionyx Corporation Limited

Lenvatinib

Eisai

Octreotide

Sun Pharma

Oxaliplatin

Teva

Irinotecan Hydrochloride Liposome

Luye Pharma Group Ltd.

Analysis

Modality Breakdown

73%

Small molecule

68 of 93 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody2224%Protein / enzyme11%Peptide11%Vaccine11%

Small molecule leads; the ring shows all 93 classified programs, each share of the total. Modality classified for 100% of 97 pipeline programs.

Analysis

Trial Status

68

clinical trials

Completed21 · 31%
Recruiting19 · 28%
Unknown status10 · 15%
Not yet recruiting6 · 9%
Terminated6 · 9%
Active, not recruiting4 · 6%
Other2 · 3%

Clinical Trials

Trial Activity

68 trials

Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma
Recruiting·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT06102746·20 enrolled
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT06202066·60 enrolled
Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas
Recruiting·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT04268121·78 enrolled
First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06070740·22 enrolled
Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)
Recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT06418087·49 enrolled
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
Recruiting·—·Phase 2·NCT04325425·218 enrolled
Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
Recruiting·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT07061080·87 enrolled
Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
Recruiting·—·Phase 2·NCT06893783·60 enrolled
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Recruiting·PPeter Hosein, MD·Phase 1·NCT06889493·36 enrolled
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
Recruiting·SShanghai Simnova Biotechnology Co.,Ltd.·Phase 1·NCT06384482·35 enrolled
Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
Recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 3·NCT06937905·129 enrolled
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06440057·78 enrolled
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT05978284·54 enrolled
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06283719·265 enrolled
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT07038096·350 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)